Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
2018; Massachusetts Medical Society; Volume: 379; Issue: 1 Linguagem: Inglês
10.1056/nejmoa1717002
ISSN1533-4406
AutoresGhassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Lorenza Rimassa, Baek‐Yeol Ryoo, İrfan Çiçin, Philippe Merle, Yen-Hsun Chen, Joong‐Won Park, Jean-Frederic Blanc, Luigi Bolondi, Heinz‐Josef Klümpen, Stephen L. Chan, Vittorina Zagonel, Tiziana Pressiani, Min-Hee Ryu, Alan P. Venook, Colin Hessel, Anne E. Borgman-Hagey, Gisela Schwab, Robin Kate Kelley,
Tópico(s)Cancer Mechanisms and Therapy
ResumoCabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the standard initial treatment for advanced disease. This randomized, double-blind, phase 3 trial evaluated cabozantinib as compared with placebo in previously treated patients with advanced hepatocellular carcinoma.
Referência(s)